Community Financial Services Group LLC Buys 3,745 Shares of Johnson & Johnson $JNJ

Posted by George Bondi on Oct 17th, 2026

Community Financial Services Group LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 67.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 9,263 shares of the company’s stock after buying an additional 3,745 shares during the quarter. Community Financial Services Group LLC’s holdings in Johnson & Johnson were worth $2,396,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in the stock. Saxony Capital Management LLC lifted its position in shares of Johnson & Johnson by 11.4% during the third quarter. Saxony Capital Management LLC now owns 2,216 shares of the company’s stock worth $587,000 after acquiring an additional 227 shares in the last quarter. Weaver Capital Management LLC raised its holdings in shares of Johnson & Johnson by 1.8% in the 3rd quarter. Weaver Capital Management LLC now owns 20,270 shares of the company’s stock valued at $5,366,000 after acquiring an additional 353 shares in the last quarter. Financial Harvest LLC boosted its position in shares of Johnson & Johnson by 3.9% during the 3rd quarter. Financial Harvest LLC now owns 1,318 shares of the company’s stock valued at $349,000 after acquiring an additional 50 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Johnson & Johnson by 54.2% during the third quarter. Assenagon Asset Management S.A. now owns 2,990,726 shares of the company’s stock worth $791,765,000 after purchasing an additional 1,051,362 shares in the last quarter. Finally, Brindle & Bay Financial Advisors LLC increased its position in shares of Johnson & Johnson by 22.1% in the third quarter. Brindle & Bay Financial Advisors LLC now owns 5,213 shares of the company’s stock worth $1,380,000 after purchasing an additional 944 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.9%

Shares of Johnson & Johnson stock opened at $255.54 on Friday. The company has a market cap of $615.82 billion, a price-to-earnings ratio of 38.72, a price-to-earnings-growth ratio of 2.50 and a beta of 0.21. The company’s 50 day moving average is $265.66 and its 200 day moving average is $249.61. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is 81.21%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president owned 23,003 shares in the company, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is owned by corporate insiders.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson?
Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target.
Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying
Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss
Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on JNJ. Citigroup increased their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Freedom Capital raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. Morgan Stanley dropped their target price on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a report on Thursday. HSBC upped their price target on Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $274.87.

Get Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.